Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protection

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 3, 2014, Pages 1055-1059

  Christensen, Dan Ploug ^a   Gysemans, Conny ^b   Lundh, Morten ^a   Dahllöf, Mattias Salling ^a   Noesgaard, Daniel ^a   Schmidt, Søren Fisker ^c   Mandrup, Susanne ^c   Birkbak, Nikolai ^d   Workman, Christopher T ^d   Piemonti, Lorenzo ^e   Blaabjerg, Lykke ^f   Monzani, Valmen ^g   Fossati, Gianluca ^g   Mascagni, Paolo ^g   Paraskevas, Steven ^h   Aikin, Reid A ^h   Billestrup, Nils ^a   Grunnet, Lars Groth ⁱ   Dinarello, Charles A ^j   Mathieu, Chantal ^b   Mandrup Poulsen, Thomas ^a,k   more..

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f HAGEDORN RESEARCH INSTITUTE   (Denmark)

^g Italfarmaco SpA   (Italy)

^h MCGILL UNIVERSITY   (Canada)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^k KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

Autoimmunity; Epigenetics; Histone deacetylase; Inflammation; Posttranslational modification

Indexed keywords

CYCLOOXYGENASE 2; FAS ANTIGEN; GAMMA INTERFERON; GIVINOSTAT; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYSINE DEACETYLASE INHIBITOR; SIRTUIN 1; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 2; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CD4+ CD25+ T LYMPHOCYTE; CELL DAMAGE; CELL DEATH; CELL PROTECTION; CHROMATIN; COMPARATIVE STUDY; CONTROLLED STUDY; DENDRITIC CELL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE EXPRESSION; HISTONE ACETYLATION; IMMUNOREGULATION; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET BETA CELL; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; WEANING;

AUTOIMMUNITY; EPIGENETICS; HISTONE DEACETYLASE; INFLAMMATION; POSTTRANSLATIONAL MODIFICATION;

ANIMALS; CELL LINE; CHROMATIN; CYTOKINES; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; FEMALE; GATA3 TRANSCRIPTION FACTOR; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INFLAMMATION; INSULIN-SECRETING CELLS; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; TIME FACTORS;

EID: 84892938274     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1320850111     Document Type: Article

References (33)

1. Bosisio D, et al. (2008) Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J Leukoc Biol 84(6):1540-1548.
2. Tao R, et al. (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 13(11):1299-1307.
3. Dinarello CA, Fossati G, Mascagni P (2011) Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol Med 17(5-6):333-352.
4. Larsen L, et al. (2007) Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells. Diabetologia 50(4):779-789.
5. Vojinovic J, Damjanov N (2011) HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis. Mol Med 17(5-6):397-403.
6. Donath MY, Størling J, Berchtold LA, Billestrup N, Mandrup-Poulsen T (2008) Cytokines and beta-cell biology: From concept to clinical translation. Endocr Rev 29(3):334-350.
7. Eldor R, et al. (2006) Conditional and specific NF-kappaB blockade protects pancreatic beta cells from diabetogenic agents. Proc Natl Acad Sci USA 103(13):5072-5077.
8. Thomas HE, Biden TJ (2009) Bad news for beta-cell apoptosis. Diabetes 58(8):1725-1727.
9. Larsen CM, et al. (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356(15):1517-1526.
10. Lundh M, et al. (2010) Lysine deacetylases are produced in pancreatic beta cells and are differentially regulated by proinflammatory cytokines. Diabetologia 53(12):2569-2578.
11. Christensen DP, et al. (2011) Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. Mol Med 17(5-6):378-390.
12. Hara N, Alkanani AK, Dinarello CA, Zipris D (2013) Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes. J Mol Med (Berl), 10.1007/s00109-013-1078-1.
13. Beier UH, et al. (2011) Sirtuin-1 targeting promotes Foxp3+ T-regulatory cell function and prolongs allograft survival. Mol Cell Biol 31(5):1022-1029.
14. Brogdon JL, et al. (2007) Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 109(3):1123-1130.
15. Song W, et al. (2011) HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells. Leukemia 25(1):161-168.
16. Larsen L, et al. (2005) Extracellular signal-regulated kinase is essential for interleukin-1-induced and nuclear factor kappaB-mediated gene expression in insulin-producing INS-1E cells. Diabetologia 48(12):2582-2590.
17. Fabre C, et al. (2008) A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts. Cell Cycle 7(14):2139-2145.
18. Batra S, Sahu RP, Kandala PK, Srivastava SK (2010) Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cells. Mol Cancer Ther 9(6):1596-1608.
19. Chen LF, Mu Y, Greene WC (2002) Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J 21(23):6539-6548.
20. Darville MI, Eizirik DL (1998) Regulation by cytokines of the inducible nitric oxide synthase promoter in insulin-producing cells. Diabetologia 41(9):1101-1108.
21. Furlan A, et al. (2011) Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357(givinostat). Mol Med 17 (5-6):353-362.
22. Vojinovic J, et al. (2011) Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 63(5):1452-1458.
23. Choi SW, et al. (2012) Targeting histone deacetylases as a new strategy for graft versus host disease prevention. Blood 120:740.
24. Kelly WK, et al. (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23(17):3923-3931.
25. Novotny-Diermayr V, et al. (2010) SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther 9(3):642-652.
26. Choi SW, et al. (2014) Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: A phase 1/2 trial. Lancet Oncol 15(1):87-95.
27. Yamagata T, et al. (2000) Acetylation of GATA-3 affects T-cell survival and homing to secondary lymphoid organs. EMBO J 19(17):4676-4687.
28. Welsh N (1996) Interleukin-1 beta-induced ceramide and diacylglycerol generation may lead to activation of the c-Jun. NH2-terminal kinase and the transcription factor ATF2 in the insulin-producing cell line RINm5F. J Biol Chem 271(14):8307-8312.
29. Larsen CM, et al. (1998) Interleukin-1beta-induced rat pancreatic islet nitric oxide synthesis requires both the p38 and extracellular signal-regulated kinase 1/2 mitogenactivated protein kinases. J Biol Chem 273(24):15294-15300.
30. Yu X, et al. (2002) Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 94(7):504-513.
31. Gysemans C, et al. (2008) Unaltered diabetes presentation in NOD mice lacking the vitamin D receptor. Diabetes 57(1):269-275.
32. Asfari M, et al. (1992) Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology 130(1):167-178.
33. Nielsen R, Grøntved L, Stunnenberg HG, Mandrup S (2006) Peroxisome proliferatoractivated receptor subtype- and cell-type-specific activation of genomic target genes upon adenoviral transgene delivery. Mol Cell Biol 26(15):5698-5714.